Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-14 |
2024-03 |
-0.11 |
-0.1 |
0.01 |
9.09% |
2024-03-19 |
2023-12 |
-0.09 |
N/A |
N/A |
N/A |
2024-03-19 |
2023-12 |
-0.09 |
0.35 |
0.44 |
488.89% |
2023-11-14 |
2023-09 |
-0.13 |
N/A |
N/A |
N/A |
2023-11-14 |
2023-09 |
-0.13 |
-0.13 |
N/A |
N/A |
2023-08-14 |
2023-06 |
-0.31 |
-0.38 |
-0.07 |
-22.58% |
Date |
Firm |
Action |
From |
To |
2023-09-19 |
Needham |
Upgrade |
Buy |
Buy |
2023-09-19 |
Truist Securities |
Upgrade |
Buy |
Buy |
2023-09-19 |
Canaccord Genuity |
Upgrade |
Buy |
Buy |
2023-08-15 |
Canaccord Genuity |
Upgrade |
Buy |
Buy |
2023-08-14 |
Needham |
Upgrade |
Buy |
Buy |
2023-08-14 |
Chardan Capital |
Upgrade |
Buy |
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2024-01-01 |
ALAM KAMRAN CPA |
Chief Financial Officer |
842.23K |
Stock Award(Grant) |
2024-05-28 |
DONENBERG PHILLIP BRIAN |
Director |
163.33K |
Stock Award(Grant) |
2024-05-28 |
LONG ALISON S |
Director |
49.22K |
Stock Award(Grant) |
2023-11-16 |
MANNING PAUL B. |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
2024-01-01 |
NAGENDRAN SUKUMAR |
President |
897.84K |
Stock Award(Grant) |
2024-01-01 |
NOLAN SEAN PATRICK |
Chief Executive Officer |
2.72M |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Group Inc |
1.59M |
1.05M |
0.85% |
2023-06-29 |
Tybourne Capital Management (HK) Limited |
1.50M |
991.50K |
0.80% |
2023-06-29 |
Artal Group S.A. |
1.44M |
952.42K |
0.77% |
2023-06-29 |
Nantahala Capital Management, LLC |
1.25M |
827.00K |
0.67% |
2023-06-29 |
Laurion Capital Management, LP |
1.17M |
774.58K |
0.63% |
2023-06-29 |
FMR, LLC |
1.15M |
759.37K |
0.61% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
1.16M |
765.12K |
0.62% |
2023-08-30 |
Fidelity Select Portfolios - Biotechnology |
811.65K |
2.60M |
0.43% |
2023-06-29 |
Vanguard Extended Market Index Fund |
384.54K |
254.18K |
0.21% |
2023-07-30 |
Franklin Strategic Series-Franklin Biotechnology Discove |
304.26K |
204.83K |
0.16% |
2023-05-30 |
Fidelity Extended Market Index Fund |
194.98K |
136.27K |
0.10% |
2023-05-30 |
Fidelity Growth Company K6 Fund |
178.67K |
124.87K |
0.10% |